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Abstract
Background Dent disease is a rare X-linked recessive proxi-
mal tubulopathy caused by mutations in CLCN5 (Dent-1) or
OCRL (Dent-2). As a rule, total protein excretion (TPE) is low
in tubular proteinuria compared with glomerular disease.
Several authors have reported nephrotic-range proteinuria
(NP) and glomerulosclerosis in Dent disease. Therefore, we
aimed to analyze protein excretion in patients with document-
ed CLCN5 or OCRL mutations in a systematic literature
review.
Design PubMed and Embase were searched for cases with
documented CLCN5 or OCRL mutations and (semi-)quanti-
tative data on protein excretion. The most reliable data (i.e.,
TPE > protein–creatinine ratio > Albustix) was used for NP
classification.
Results Data were available on 148 patients from 47 reports:
126 had a CLCN5 and 22 an OCRLmutation. TPE was not
significantly different between both forms (p = 0.11). Fifty-
five of 126 (43.7 %) Dent-1 vs 13/22 (59.1 %) Dent-2 patients
met the definition of NP (p = 0.25). Serum albumin was nor-
mal in all reported cases (24/148). Glomerulosclerosis was
noted in 20/32 kidney biopsies and was strongly related to
tubulointerstitial fibrosis, but not to kidney function or
proteinuria.
Conclusion More than half of the patients with both forms of
Dent disease have NP, and the presence of low molecular
weight proteinuria in a patient with NP in the absence of
edema and hypoalbuminemia should prompt genetic testing.
Even with normal renal function, glomerulosclerosis and
tubulointerstitial fibrosis are present in Dent disease. The role
of proteinuria in the course of the disease needs to be exam-
ined further in longitudinal studies.
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Introduction
Dent disease, a rare X-linked recessive tubulopathy, was first
described in 1964 in two unrelated cases presenting with renal
tubular rickets, hypercalciuria, and tubular proteinuria [1].
Dent disease is characterized by low molecular weight
(LMW) proteinuria, hypercalciuria, nephrolcalcinosis or
nephrolithiasis, variable manifestations of proximal tubular
dysfunction, and progressive renal failure, ultimately resulting
in end-stage renal failure in adulthood [2–5].
In about 60 % of patients with X-linked nephrolithiasis, a
mutation in the CLCN5 gene is detected, whereas in 15 %, the
disease is due to a mutation in theOCRL gene. For the remain-
ing 25 %, no specific gene defect has been described as yet
[6]. Patients with a mutation in CLCN5 are classified as hav-
ing Dent disease type 1 (Dent-1; MIM #300009), while pa-
tients with a mutation in OCRL are classified as Dent disease
type 2 (Dent-2; MIM #300555). The renal phenotype of Dent-
2 is comparable with that of Dent-1 except for a lower prev-
alence of nephrocalcinosis [7, 8]. The exact prevalence of
Dent disease is unknown; to date, >250 families have been
described [9].
Under normal conditions, LMW proteins, which pass the
glomerular membrane extensively [10], are almost completely
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reabsorbed in the proximal tubule by megalin-cubilin recep-
tor-mediated endocytosis and therefore do not appear in the
final urine. As CLCN5 and OCRL mutations impair the func-
tion of the megalin–cubilin system, the loss of LMW proteins
is an obligate finding in Dent disease [11]. As a rule, total
protein excretion is low in tubular proteinuria compared with
glomerular disease, mostly around 1 g/l, and rarely exceeds
2 g/l [12]. Frishberg et al. [2], Copelovitch et al. [13], and
Fervenza [14] reported nephrotic-range proteinuria (NP) in
patients with documented CLCN5 mutations and histological
findings of focal segmental glomerulosclerosis (FSGS) or fo-
cal global glomerulosclerosis. They suggested that Dent-1
disease is an underdiagnosed etiology of FSGS and might
reflect a yet unrecognized glomerular dysfunction in Dent-1,
while data on proteinuria in Dent-2 are sparse [15]. Therefore,
the objective of this study was to analyze protein excretion
and histology in patients with documented CLCN5 or OCRL
mutation disease by means of a systematic literature review
(Fig. 1).
Methods
Our search was performed using the bibliographic search en-
gines PubMed and Embase using the following search
strategy:
For Dent-1: [Dent’s disease OR Dents disease OR Dent
disease OR Dent Disease (Mesh)] AND [CLCN5 OR
CLCN-5 OR CLCN 5 OR CLCN OR CLC-5 chloride
channel (Supplementary Concept) OR Dent disease 1
(Supplementary Concept)]
For Dent-2: Dent’s disease OR Dents disease OR Dent
disease OR Dent Disease (Mesh)] AND [OCRL1 OR
OCRL-1 OR OCRL 1 OR OCRL OR Dent disease 2
(Supplementary Concept)].
The combined search on Embase and PubMed yielded a
total of 761 unique records, all of which were screened man-
ually by title and abstract by two independent researchers
(YvB and AB). Inclusion criteria were papers describing (i)
Dent disease patients with documented CLCN5 orOCRLmu-
tations, and (ii) presenting quantitative or semiquantitative
data on proteinuria. Main exclusion criteria were cases with
extrarenal findings, suggesting Lowe syndrome inOCRL-pos-
itive patients, and papers reporting female carriers only. Only
papers published in English were considered for review. The
reference lists of the respective papers were checked for pub-
lications missed by the search strategy.
Data on total protein excretion were extracted if presented
as (i) semiquantitative Albustix in a spot urine sample
(Sticks), (ii) protein–creatinine ratio in a spot urine sample
(P/C), or (iii) as protein excretion in a timed urine collection.
Timed protein excretion (TPE) was related to total body sur-
face area (BSA) and presented as milligrams per meter2 per
hour. BSA was calculated from weight and height using the
Mosteller formula [16]. In 54 patients with documented timed
proteinuria, no height/weight data were available, however. In
these cases, BSA was estimated as follows: in adults, a stan-
dard BSA of 1.73 m2 was used, while in children, height and
weight were extrapolated using Dutch reference data of
gender- and age-specific medians for height and weight [17].
To validate this approach, we compared TPE based on extrap-
olated BSA, with TPE calculated from documented height and
weight in 28 patients. Median TPE based on extrapolated
BSA was 52.1 mg/m2/h [interquartile range (IQR) 40.3–
71.2] compared with 51.6 mg/m2/h with documented height
and weight (IQR 35.8–71.6, p = 0.699, Wilcoxon test), indi-
cating that our approach yields valid results. If TPE was
expressed as milligrams per kilogram per day, it was trans-
formed into milligrams per meter2 per hour by analogy.
The following definitions were used: LMW proteinuria
was defined as increased excretion of either β2 microglobulin
(β2M) (>0.3 mg/l or >0.3 mg/g creatinine), retinol-binding
protein (RBP) (>0.1 mg/l or >0.1 mg/g creatinine), or α1 mi-
croglobulin (α1M) (>12 mg/l or >11.7 mg/g creatinine) [18,
19]. NP was defined as TPE > 40 mg/m2/h [20] or P/C >
1800 mg/g creatinine (corresponding to >200 mg/mmol cre-
atinine) [21] or Sticks 3+ [21]. If more than one parameter was
available, the most reliable (i.e. TPE > P/C > sticks) was used
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for NP classification. Unless glomerular filtration rate (GFR)
was stated in the paper, it was estimated using the Schwartz
equation in children [22] or the four variable Modification of
Diet in Renal Disease (MDRD) equation in adults [23]. As
functional data are lacking for mostmutations, mutations lead-
ing to messenger RNA (mRNA) decay or premature termina-
tion of the resultant OCRL-1 or ClC-5 protein (i.e., stop,
frameshift, gross deletion) were classified as severe, while
frame and missense mutations were classified as moderate
[24].
Serial data were available on only 13 patients. In these
cases, data at presentation were used. Statistical analysis was
performed using SPSS version 22 [25]. Data are presented as
median [interquartile range (IQR)] and were analyzed using
nonparametric tests (chi-square and Mann–Whitney U).
Differences were considered significant at p <0.05, and p
<0.1 was considered as a statistical trend.
Results
Study characteristics
As of 1 March 2016, the PubMed and Embase search yielded
a total of 761 publications after removing 499 duplicates. Six
hundred and fifty-three were excluded based on title and ab-
stract (130 involved animal studies, 127 reported on Lowe
syndrome, 62 were reviews, 54 were not in English, and 280
were irrelevant to our study). The remaining 108 articles were
reviewed in full text: 61 were excluded (49 presented non-
quantitative data, diagnosis of Dent disease had not been con-
firmed genetically in ten, and two papers contained cases al-
ready reported in another publication). In total, 47 articles
describing 148 patients were included [2, 5, 13–15, 26–67].
The median number of patients per publication was two (IQR
1–5). Sixty-one patients were reported in papers from Japan,
China, Korea, or India; 24 from North America; three from
South America; 55 from the Mediterranean; and five from
Northern Europe. One hundred and-twenty-six patients had
a CLCN5 and 22 an OCRL mutation. Median age was
8.5 years (IQR 4–13) in Dent-1 and 9 years (IQR 4–10.5) in
Dent-2. Data on GFR were available in 110 patients with
Dent-1 and 19 with Dent-2. Here, too, no significant differ-
ence was found [110.5 ml/min/1.73 m2 (IQR 79–143) vs.
108 ml/min/1.73 m2 (IQR 94–130); p = 0.971].
Proteinuria
Data on proteinuria are presented in Table 1. In the majority of
patients, TPE was reported. There was no difference in pro-
teinuria between Dent-1 and Dent-2 patients based on TPE,
while Dent-2 patients scored higher when proteinuria was
tested by urinary dipstick. In both groups, almost half of the
patients had NP. Quantitative LMW proteinuria was reported
in 134 patients. β2Mwas by far the most frequently measured
LMW protein and was reported in 85.1 % of patients; the vast
majority of papers reported LMW protein concentrations rath-
er than LMW protein/creatinine ratios or TPE. This was also
the case for urinary albumin excretion, which was reported in
only 11 patients [median 200 mg/l (IQR 80–310)]. This pre-
cluded further analysis of urinary protein composition. There
was no significant relationship between TPE and GFR (r2 =
0.032, p = 0.15). Accordingly, GFR was comparable between
patients with and without NP [104.1 ml/min/1.73 m2 (IQR
79–121.6) vs. 118.3 ml/min/1.73 m2 (IQR 83.6–173.9); p =
0.327)] There was no single report mentioning edema forma-
tion in Dent patients. Serum albumin was reported in 24 cases:
median concentration was 46.5 (39–54) g/l.
Information on renin–angiotensin–aldosterone system
(RAAS) inhibition was available for eight patients only.
Angiotensin-converting enzyme (ACE) inhibitors or an-
giotensin II receptor blockers (ARB) were prescribed for
eight Dent-1 patients (Table 2): all but one had NP; a re-
duction of proteinuria of 50 % was reported for two; pro-
teinuria remained unchanged in four. In one patient, RAAS
inhibition was discontinued because of rapidly rising se-
rum creatinine. In two others, GFR halved within 4 and
7 years, respectively.
Mutation
In 44 of 148 patients (29.7 %), mutation severity was classi-
fied as moderate. In this group, the prevalence of NP was
comparable with patients harboring a severe mutation
(52.3 % vs 43.3 %, p = 0.368), as was proteinuria [TPE
60.0 mg/m2/h (IQR 39.9–77.6) vs. 46.1 mg/m2/h (IQR
36.5–64.2, p = 0.205) and GFR [113.9 ml/min/1.73 m2 (IQR
74.4–162.4) vs 108.2 ml/min/1.73 m2 (IQR 81–138), p =
0.584).
Kidney biopsy
Kidney biopsy data were reported in 34 patients: 31 Dent-1
and three Dent-2. Proteinuria [TPE 52.1 mg/m2/h (IQR 39–
69) vs. 48.8 mg/m2/h (IQR 37–78), p = 0.80) and GFR
[118 ml/min/1.73 m2 (IQR 83–166) vs. 109 ml/min/
1.73 m2 (IQR 79–140), p = 0.51] were comparable be-
tween biopsied and nonbiopsied patients. Median age at
biopsy was 9 years, which is identical with the median
age of the total cohort. Table 3 summarizes biopsy results.
In ten patients, glomeruli were reported to be normal; in
two, immature glomeruli were noted; and in two, no infor-
mation was provided. Glomerular sclerosis was noted in 20
of the 32 biopsies describing glomerular morphology
(63 %), namely, focal global glomerulosclerosis (N = 18)
ra ther than FSGS (N = 5) . In pa t ien t s in whom
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glomerulosclerosis was quantified, a median of 13 % (IQR
6–26) of glomeruli was affected. Only four papers reported
electron microscopy data on glomerular foot processes: in
a single patient [44], foot-process effacement was noted; in
the other three, electron microscopy was normal [27, 36,
42]. Tubulointerstitial fibrosis was present in 14 of 29 pa-
tients (48 %) and nephrocalcinosis in ten of 14 (71 %) in
whom these features were reported. Contingency table
analysis between glomerular sclerosis and tubulointerstitial
fibrosis showed a highly significant association (χ2 = 19.1,
p = 0.001). There was no statistical difference in median
TPE with respect to glomerulosclerosis [with 49.1 mg/
m2/h (IQR 37–78) vs. without 65.8 mg/m2/h (IQR 52–
69), p = 0.1] or tubulointerstitial fibrosis [with 49.1 mg/
m2/h (IQR 33–84) vs. without 61.8 mg/m2/h (IQR 47–
68), p = 0.238]. Of note, both histological findings ap-
peared to be associated with less rather than more
proteinuria.
Discussion
We demonstrated that NP is a common finding in Dent disease
both in patients with CLCN5 and OCRL mutations. Still, pa-
tients do not present with the other two characteristics of ne-
phrotic syndrome (NS), i.e., edema formation or hypoalbu-
minemia. Therefore, the finding of isolated NP should prompt
analysis for LMW proteinuria. Although LMW proteinuria
can be seen as a result of overflow proteinuria in patients with
massive proteinuria, this phenomenon is not observed in the
proteinuria range of Dent patients [68]. Two mechanisms may
be involved in the pathogenesis of NP in Dent disease: defec-
tive uptake of physiologically filtered albumin and other pro-
teins, or an additional glomerulopathy as suggested by the
presence of glomerulosclerosis on renal biopsy [2, 13, 14].
Although it was held that CLCN5 is only expressed in prox-
imal tubuli and collecting ducts, Ceol et al. recently showed
CLCN5 expression in human podocytes [69]. As CLCN5







ARB T = 0 T = 1 Treatment
duration
Copelovitch et al. [13] Patient 1 CLCN5 12 Yes No Proteinuria: 50 mg/kg/day Proteinuria: 25 mg/kg day 2 months
Frishberg et al. [2] Patient 1 CLCN5 9 Yes Yes NA No effect on proteinuria NA
Patient 3 CLCN5 14 Yes Yes NA No effect on proteinuria NA
Lim et al. [44] Case 1 CLCN5 3 Yes No NA 50 % P/C reduction 6 months
Marsenic et al. [47] Patient 1 CLCN5 13 Yes No NA Strong rise in serum creatinine NA
Okamoto et al. [52] Case 1 CLCN5 3 Yes No GFR 73 ml/min/1.73 m2 GFR 30 ml/min/1.73 m2 7 years
Vaisbich et al. [63] Case 1 CLCN5 11 Yes No Proteinuria: 51 mg/kg day
GFR 66 ml/min/1.73 m2
Proteinuria: 65 mg/kg day
GFR 65 ml/min/1.73 m2
3 years 5 months
Case 2 CLCN5 4 Yes No Proteinuria: 65 mg/kg day
GFR 172 ml/min/1.73 m2
Proteinuria: 60 mg/kg day
GFR 95 ml/min/1.73 m2
4 years
ARB angiotensin II receptor-blockers, ACE angiotensin-converting enzyme, GFR glomerular filtration rate, T = 0 before therapy, T = 1 during therapy
Table 1 Proteinuria in Dent-1 and Dent-2 patients
Total Dent-1 Dent-2 P value
Dipstick (n) N = 63 N = 52 N = 11 0.02
1+ 18 (27.3 %) 17 (30.9 %) 1 (9.1 %)
2+ 40 (60.6 %) 34 (61.8 %) 6 (54.5 %)
3+ 7 (10.6 %) 3 (5.5 %) 4 (36.4 %)
4+ 1 (1.5 %) 1 (1.8 %) 0 (0 %)
P/C (mg/g) N = 23 N = 20 N = 3 NA
2800 (2100–4104) 2850 (1835–4900) 2718 (NA)
TPE (mg/m2/h) N = 83 N = 71 N = 12 0.11
49.0 (38.1–69.1) 47.0 (37.3–67.4) 57.5 (41.8–81.1)
NP (N/N) 68/148 (45.9 %) 55/126 (43.7 %) 13/22 (59.1 %) 0.25
Data presented as number (%) of cases or as median and interquartile range (IQR)























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































appeared to be overexpressed in proteinuric states, the authors
speculate that podocytes have an endocytic machinery similar
to the proximal tubular cell. This has been linked to the finding
of glomerulosclerosis in Dent-1 patients [14]. Studies in rabbits
showed that OCRL, too, is expressed in glomeruli [70]. This
prompted us to compare the proteinuric phenotype in both
forms of Dent disease, which share a common metabolic path-
way in the proximal tubule. In line with findings on renal–
tubular dysfunction in both patient groups [11], we found that
proteinuria was virtually identical, suggesting defective protein
uptake as the underlying mechanism.
Can defective protein uptake by the megalin–cubilin complex
alone account for the amount of proteinuria observed in these
patients? While LMW proteins are almost freely filtered across
the glomerular membrane, there is much controversy about glo-
merular albumin filtration, with sieving coefficients ranging from
0.0006 to 0.074 in different ratmodels [71]. This has recently been
reviewed by Dickson et al., who suggest that glomerular albumin
filtration is higher than previously thought and that part of the
filtered albumin is reabsorbed intact via transcytosis involving
the neonatal Fc receptor [72]. Norden et al. studied patients with
Dent disease to calculate the glomerular sieving coefficients of
albumin, immunoglobulin (Ig) G and other plasma proteins
in vivo, assuming that in these patients, urinary protein excretion
directly reflects glomerular protein filtration [10]. They report a
sieving coefficient for albumin of 0.00008 and a mean urine
albumin/creatinine ratio of 38mg/mmol (i.e. 342mg/g creatinine).
In another study on tubular proteinuria in Dent disease,
Norden et al. reported a linear relationship between the
albumin/creatinine ratio and the creatinine-corrected concentra-
tions of retinol-binding protein, β2M, and alpha-1 microglobu-
lin, all of which were around 20–30 mg/mmol creatinine (i.e.,
180–270 mg/g) [18]. The sum of the mean albumin, retinol-
binding protein,β2M, and alpha-1 microglobulin concentrations
standardized for urine creatinine was 100 mg/mmol (i.e.,
900 mg/g), which is about one third of the proteinuria observed
in our study. This probably reflects the multitude of other LMW
proteins and polypeptides undergoing tubular reabsorption,
which were not measured in their study. Of note, intermittent
nephrotic-range proteinuria has also been observed in a pair of
siblings with a mutation in CUBN encoding for cubilin, whereas
most of these patients only have LMW proteinuria [73].
Kidney biopsy data were only available for ∼20% of patients
and might be flawed by a reporting bias. Still, patient age, renal
function, and amount of proteinuria were identical to those of
nonbiopsied patients. When reported, the number of glomeruli
was sufficient to exclude a serious sampling error. The finding of
glomerulosclerosis in almost two thirds of the biopsies (with a
median of 17% glomeruli being sclerosed) underscores the con-
cerns about glomerular pathology in Dent disease. However,
glomerulosclerosis was mostly focal global rather than focal
segmental [2, 13, 14]. The absence of foot-process effacement
(when reported) and themissing association between the amount
of proteinuria and tubulointerstitial fibrosis or the presence of
glomerulosclerosis, points toward a primary tubulointerstitial
process leading to glomerular sclerosis. This fits with the strong
association between glomerulosclerosis and tubulointerstitial fi-
brosis, which was also found by Theilig et al. in megalin-
knockout mice [74]. In their model, megalin deficiency was
associated with increased apoptosis at baseline, which was ac-
centuated following induction of anti-glomerular-basement-
membrane (GBM) nephritis. Recent studies in a model of iso-
lated proximal tubular damage have shown that tubulointerstitial
injury can lead to glomerulosclerosis [75, 76].
Reports regarding RAAS inhibition in Dent disease are
scarce, and most of them report disappointing results. RAAS
inhibition is the treatment of choice for glomerular proteinuria
originating either from glomerulonephritis, Alport syndrome,
or primary or secondary FSGS. Based on the strong association
between urinary albumin excretion and renal endpoints,
Heerspink and Gansevoort argue that normalization of urinary
albumin excretion should be a therapeutic target per se [77].
They show that the beneficial effect of RAAS inhibition is
conveyed via normalization of albuminuria. Does this also ap-
ply to albuminuria resulting from defective tubular reabsorp-
tion? There is a large body of evidence mostly from in vitro
studies indicating that an overload of albumin in primary urine
triggers a toxic effect and inflammatory response in proximal
tubular cells conveyed via the megalin–cubilin system [77]. In
their study on anti-GBM disease in megalin-knockout mice,
Theilig et al. indeed observed increased expression of
profibroticmarkers in amegalin-dependent manner [74]. In this
light, disturbed endocytosis—as in Dent disease—might be
expected to protect the proximal tubular cells against the detri-
mental effects of albuminuria. However, tubulointerstitial fibro-
sis was most marked in knockout animals, leading the authors
to challenge the view of protein overload causing
tubulointerstitial damage. Norden et al. demonstrated tubular
wasting of a wide variety of polypeptides, hormones (e.g., in-
sulin, growth hormone, insulin-like growth factor-1), and
chemokines (e.g., monocyte chemoattractant protein-1) [10].
Some of these have been implicated in the pathogenesis of
tubulointerstitial fibrosis and may be the underlying mecha-
nism for progressive renal failure in Dent disease.
Due to the nature of a review based on case reports, our study
has several limitations: (i) The number of reportedDent-2 patients
is far less than that of Dent-1 patients; therefore, nonparametric
tests had to be used, which may have weakened the statistical
power of our analysis. Still, the findings in both patient groups
were virtually identical, indicating that our conclusion that Dent-1
and Dent-2 are phenotypically identical as far as proteinuria is
concerned holds true. (ii) Data were analyzed retrospectively,
and data sets were incomplete for many parameters. In particular,
for TPE, assumptions were made regarding BSA based on Dutch
reference values, while the literature survey identified mostly pa-
tients fromAsia and theMediterranean. As theDutch are taller on
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average than these populations, BSA has probably been
overestimated in our analysis. Therefore, TPEwill be even higher
than estimated. The lower prevalence of NP by dipstick analysis
compared with quantitative methods reflects the limitation of this
test for detecting LMW proteinuria. Data on albuminuria was
scarce, precluding a specific analysis of protein composition.
(iii) In particular, in patients with high protein excretion, a publi-
cation bias cannot be excluded. However, the majority of reports
did not focus on proteinuria and did not even discuss the amount
of protein excretion, indicating that our findings on median pro-
tein excretion are representative for Dent patients. (iv) Patients
were rather young in our series and had normal GFR. Also, there
was insufficient data for serial analysis, and thus our data cannot
be extrapolated to older Dent patients, and the prognostic role of
proteinuria in Dent disease remains unclear. Here, prospective
long-term studies are needed to evaluate the impact of proteinuria
and hypercalciuria/nephrocalcinosis for the prognosis of Dent dis-
ease. Such studies are underway (http://www.rarekidneystones.
org). Potential therapeutic interventions to be tested are thiazide
diuretics, citrate, and RAAS inhibition [3]. Regardless, the slow
natural course of Dent disease leading to end-stage renal disease
in later adulthood is a major obstacle for prospective
(interventional) studies. Animal studies such as the citrate trial
in knockout mice performed by Cebotaru et al. [78] may be more
informative than studies in humans using surrogate markers such
as hypercalciuria [79] or proteinuria.
Conclusion
Nephrotic-range proteinuria is a common finding both in
Dent-1 and Dent-2 and reflects disturbed protein reabsorption
in the proximal tubule rather than glomerular damage. The
presence of LMW proteinuria is the hallmark of Dent disease
and should be tested in patients with nephrotic-range protein-
uria without edema and hypoalbuminemia in order to avoid
potentially harmful immunosuppressive therapy and unneces-
sary renal biopsies. Even with normal renal function,
glomerulosclerosis and tubulointerstitial fibrosis are already
present in the majority of patients in childhood. The role of
proteinuria in the course of the disease needs to be studied
further in longitudinal (interventional) studies.
Compliance with ethical standards
Conflict of interest The authors declare no conflicts of interest.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Dent CE, FriedmanM (1964) Hypercalcuric rickets associated with
renal tubular damage. Arch Dis Child 39:240–249
2. Frishberg Y, Dinour D, Belostotsky R, Becker-Cohen R, Rinat C,
Feinstein S, Navon-Elkan P, Ben-Shalom E (2009) Dent’s disease
manifesting as focal glomerulosclerosis: is it the tip of the iceberg?
Pediatr Nephrol 24:2369–2373
3. Ludwig M, Utsch B, Monnens LA (2006) Recent advances in un-
derstanding the clinical and genetic heterogeneity of Dent’s disease.
Nephrol Dial Transplant 21:2708–2717
4. Thakker RV (2000) Pathogenesis of Dent’s disease and related syn-
dromes of X-linked nephrolithiasis. Kidney Int 57:787–793
5. Vrljicak K, Batinic D, Milosevic D, Nizic-Stancin L, Ludwig M
(2011) A boy with Dent-2 disease. Coll Anthropol 35:925–928
6. Bockenhauer D, Bokenkamp A, Nuutinen M, Unwin R, Van’t Hoff
W, Sirimanna T, Vrljicak K, Ludwig M (2012) Novel OCRL mu-
tations in patients with Dent-2 disease. J Pediatr Genet 1:15–23
7. Bokenkamp A, Ludwig M (2011) Disorders of the renal proximal
tubule. Nephron Physiol 118:1–6
8. WrongOM, NordenAG, Feest TG (1994) Dent’s disease; a familial
proximal renal tubular syndrome with low-molecular-weight pro-
teinuria, hypercalciuria, nephrocalcinosis, metabolic bone disease,
progressive renal failure and a marked male predominance. QJM
87:473–493
9. Devuyst O, Thakker RV (2010)Dent’s disease. Orphanet J Rare Dis
5:28
10. Norden AG, Lapsley M, Lee PJ, Pusey CD, Scheinman SJ, Tam
FW, Thakker RV, Unwin RJ, Wrong O (2001) Glomerular protein
sieving and implications for renal failure in Fanconi syndrome.
Kidney Int 60:1885–1892
11. Bokenkamp A, Bockenhauer D, Cheong HI, Hoppe B, Tasic V,
Unwin R, Ludwig M (2009) Dent-2 disease: a mild variant of
Lowe syndrome. J Pediatr 155:94–99
12. Israni A, Kasiske B (2004) Laboratory assessment of kidney dis-
ease: clearance, urinalysis, and kidney biopsy. Brenner and Rector’s
the kidney - 7th ed. Philadelphia: Saunders., United States, p 742
13. Copelovitch L, Nash MA, Kaplan BS (2007) Hypothesis: Dent
disease is an underrecognized cause of focal glomerulosclerosis.
Clin J Am Soc Nephrol 2:914–918
14. Fervenza FC (2013) A patient with nephrotic-range proteinuria and
focal global glomerulosclerosis. Clin J Am Soc Nephrol 8:1979–
1987
15. De Mutiis C, Pasini A, La Scola C, Pugliese F, Montini G (2015)
Nephrotic-range Albuminuria as the presenting symptom of Dent-2
disease. Ital J Pediatr 41:46
16. Mosteller RD (1987) Simplified calculation of body-surface area. N
Engl J Med 317:1098
17. Netherlands Organisation for Applied Scientific Research (TNO):
‘Growth Chart Boys 0–15 Months’ and ‘Growth Chart Boys 1–21
Years’: Fifth national growth studie 2010. http://www.tno.
nl/en/focus-area/healthy-living/prevention-work-health/youth-
growing-up-healthy/pdf-growth-charts/
18. Norden AG, Scheinman SJ, Deschodt-Lanckman MM, Lapsley M,
Nortier JL, Thakker RV, Unwin RJ, Wrong O (2000) Tubular pro-
teinuria defined by a study of Dent’s (CLCN5 mutation) and other
tubular diseases. Kidney Int 57:240–249
19. Guder WG, Hofmann W (1993) Differentiation of proteinuria and
haematuria by single protein analysis in urine. Clin Biochem 26:
277–282
20. Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, Pasini
A, Montini G, Edefonti A, Belingheri M, De Giovanni D, Barbano
G, Degl’Innocenti L, Scolari F, Murer L, Reiser J, Fornoni A,
Ghiggeri GM (2015) Rituximab in children with steroid-
dependent nephrotic syndrome: a multicenter, open-label,
Pediatr Nephrol
noninferiority, randomized controlled trial. J Am Soc Nephrol 26:
2259–2266
21. Levey A, Coresh J (2002) Clinical practice guidelines for chronic
kidney disease: evaluation, classification and stratification. National
K i d n e y F o u n d a t i o n ; h t t p : / / w w w . k i d n e y .
org/sites/default/files/docs/ckd_evaluation_classification_
stratification.pdf
22. Schwartz GJHG, Edelmann CM Jr, Spitzer A (1976) A simple
estimate of glomerular filtration rate in children derived from body
length and plasma creatinine. Pediatrics 58:259–263
23. Levey AS, Coresh J, Greene T, Stevens LA, ZhangYL, Hendriksen
S, Kusek JW, Van Lente F (2006) Using standardized serum creat-
inine values in the modification of diet in renal disease study equa-
tion for estimating glomerular filtration rate. Ann Intern Med 145:
247–254
24. Hichri H, Rendu J,Monnier N, CouttonC, Dorseuil O, Poussou RV,
Baujat G, Blanchard A, Nobili F, Ranchin B, Remesy M, Salomon
R, Satre V, Lunardi J (2011) From Lowe syndrome to Dent disease:
correlations betweenmutations of the OCRL1 gene and clinical and
biochemical phenotypes. Hum Mutat 32:379–388
25. IBM-Corp (Released 2013) IBM SPSS Statistics for Windows,
Version 22.0. Armonk, NY: IBM Corp
26. Akuta N, Lloyd SE, Igarashi T, Shiraga H,Matsuyama T, Yokoro S,
Cox JP, Thakker RV (1997) Mutations of CLCN5 in Japanese chil-
dren with idiopathic low molecular weight proteinuria, hypercalci-
uria and nephrocalcinosis. Kidney Int 52:911–916
27. Anglani F, Bernich P, Tosetto E, Cara M, Lupo A, Nalesso F,
D’Angelo A, Gambaro G (2006) Family history may be misleading
in the diagnosis of Dent’s disease. Urol Res 34:61–63
28. Becker-Cohen R, Rinat C, Ben-Shalom E, Feinstein S, Ivgi H,
Frishberg Y (2012) Vitamin A deficiency associated with urinary
retinol binding protein wasting in Dent’s disease. Pediatr Nephrol
27:1097–1102
29. Besbas N, Ozaltin F, Jeck N, Seyberth H, Ludwig M (2005)
CLCN5mutation (R347X) associated with hypokalaemic metabol-
ic alkalosis in a Turkish child: an unusual presentation of Dent’s
disease. Nephrol Dial Transplant 20:1476–1479
30. Bogdanovic R, Draaken M, Toromanovic A, Crossed Devic M,
Stajic N, LudwigM (2010) A novel CLCN5mutation in a boy with
Bartter-like syndrome and partial growth hormone deficiency.
Pediatr Nephrol 25:2363–2368
31. Carballo-Trujillo I, Garcia-Nieto V, Moya-Angeler FJ, Anton-
Gamero M, Loris C, Mendez-Alvarez S, Claverie-Martin F
(2003) Novel truncating mutations in the ClC-5 chloride channel
gene in patients with Dent’s disease. Nephrol Dial Transplant 18:
717–723
32. CheongHI, Lee JW, Zheng SH, Lee JH, Kang JH, KangHG, Ha IS,
Lee SJ, Choi Y (2005) Phenotype and genotype of Dent’s disease in
three Korean boys. Pediatr Nephrol 20:455–459
33. Claverie-Martin F, Gonzalez-Acosta H, Flores C, Anton-Gamero
M, Garcia-Nieto V (2003) De novo insertion of an Alu sequence
in the coding region of the CLCN5 gene results in Dent’s disease.
Hum Genet 113:480–485
34. Cramer MT, Charlton JR, Fogo AB, Fathallah-Shaykh SA,
Askenazi DJ, Guay-Woodford LM (2014) Expanding the pheno-
type of proteinuria in Dent disease. A case series. Pediatr Nephrol
29:2051–2054
35. Dinour D, Davidovitz M, Levin-Iaina N, Lotan D, Cleper R,
Weissman I, Knecht A, Holtzman EJ (2009) Truncating mutations
in the chloride/proton ClC-5 antiporter gene in Seven Jewish Israeli
families with Dent’s 1 disease. Nephron Clin Pract 112:c262–267
36. Hellemans R, Verpooten GA, Bosmans JL (2010) A young man
presenting with recurrent nephrolithiasis. NDT Plus 3:584–587
37. Hoopes RR Jr, Hueber PA, Reid RJ Jr, Braden GL, Goodyer PR,
Melnyk AR, Midgley JP, Moel DI, Neu AM, VanWhy SK,
Scheinman SJ (1998) CLCN5 chloride-channel mutations in six
new North American families with X-linked nephrolithiasis.
Kidney Int 54:698–705
38. Igarashi T, Inatomi J, Ohara T, Kuwahara T, Shimadzu M, Thakker
RV (2000) Clinical and genetic studies of CLCN5 mutations in
Japanese families with Dent’s disease. Kidney Int 58:520–527
39. Igarashi T, GuntherW, Sekine T, Inatomi J, Shiraga H, Takahashi S,
Suzuki J, Tsuru N, Yanagihara T, Shimazu M, Jentsch TJ, Thakker
RV (1998) Functional characterization of renal chloride channel,
CLCN5, mutations associated with Dent’sJapan disease. Kidney
Int 54:1850–1856
40. Kaneko K, Hasui M, Hata A, Hata D, Nozu K (2010) Focal seg-
mental glomerulosclerosis in a boy with Dent-2 disease. Pediatr
Nephrol 25:781–782
41. Kelleher CL, Buckalew VM, Frederickson ED, Rhodes DJ, Conner
DA, Seidman JG, Seidman CE (1998) CLCN5 mutation
Ser244Leu is associated with X-linked renal failure without X-
linked recessive hypophosphatemic rickets. Kidney Int 53:31–37
42. Langlois V, Bernard C, Scheinman SJ, Thakker RV, Cox JP,
Goodyer PR (1998) Clinical features of X-linked nephrolithiasis
in childhood. Pediatr Nephrol 12:625–629
43. Li P, Huang JP (2009) Phenotype and genotype of Dent’s disease in
three Chinese boys. Nephrology (Carlton) 14:139–142
44. Lim IS, YunKW,MoonKC, Cheong HI (2007) Proteinuria in a boy
with infectious mononucleosis, C1q nephropathy, and Dent’s dis-
ease. J Korean Med Sci 22:928–931
45. Lloyd SE, Pearce SH, Gunther W, Kawaguchi H, Igarashi T,
Jentsch TJ, Thakker RV (1997) Idiopathic low molecular weight
proteinuria associated with hypercalciuric nephrocalcinosis in
Japanese children is due to mutations of the renal chloride channel
(CLCN5). J Clin Invest 99:967–974
46. Lozanovski VJ, Ristoska-Bojkovska N, Korneti P, Gucev Z, Tasic
V (2011) OCRL1 mutation in a boy with Dent disease, mild mental
retardation, but without cataracts. World J Pediatr 7:280–283
47. Marsenic O, Kaplan BS (2009) Hydrochlorothiazide-induced
tubulointerstitial nephritis in a patient with Dent disease. NDT
Plus 2:264–265
48. Matsuyama T, AwazuM, Oikawa T, Inatomi J, Sekine T, Igarashi T
(2004) Molecular and clinical studies of Dent’s disease in Japan:
biochemical examination and renal ultrasonography do not predict
carrier state. Clin Nephrol 61:231–237
49. Morimoto T, Uchida S, Sakamoto H, Kondo Y, Hanamizu H, Fukui
M, Tomino Y, Nagano N, Sasaki S, Marumo F (1998) Mutations in
CLCN5 chloride channel in Japanese patients with low molecular
weight proteinuria. J Am Soc Nephrol 9:811–818
50. Nakazato H, Yoshimuta J, Karashima S, Matsumoto S, Endo F,
Matsuda I, Hattori S (1999) Chloride channel CLCN5 mutations
in Japanese children with familial idiopathic low molecular weight
proteinuria. Kidney Int 55:63–70
51. Nakazato H, Hattori S, Furuse A, Kawano T, Karashima S, Tsuruta
M, Yoshimuta J, Endo F, Matsuda I (1997) Mutations in the
CLCN5 gene in Japanese patients with familial idiopathic low-
molecular-weight proteinuria. Kidney Int 52:895–900
52. Okamoto T, Tajima T, Hirayama T, Sasaki S (2012) A patient with
Dent disease and features of Bartter syndrome caused by a novel
mutation of CLCN5. Eur J Pediatr 171:401–404
53. Ramos-Trujillo E, Garcia-Nieto V, Gonzalez-Acosta H, Vara J,
Perez-Diaz V, Nadal I, Oliveros R, Claverie-Martin F (2007)
Molecular analysis of the CLCN5 gene in Dent’s disease: first mu-
tation identified in a patient from South America. Clin Nephrol 68:
367–372
54. SamardzicM, Pavicevic S, LudwigM, Bogdanovic R (2011) Effect
of growth hormone replacement therapy in a boy with Dent’s dis-
ease: a case report. J Med Case Rep 5:400
55. Sekine T, Nozu K, Iyengar R, Fu XJ, Matsuo M, Tanaka R, Iijima
K, Matsui E, Harita Y, Inatomi J, Igarashi T (2007) OCRL1
Pediatr Nephrol
mutations in patients with Dent disease phenotype in Japan. Pediatr
Nephrol 22:975–980
56. Sethi SK, Ludwig M, Kabra M, Hari P, Bagga A (2009) Vitamin A
responsive night blindness in Dent’s disease. Pediatr Nephrol 24:
1765–1770
57. Sheffer-Babila S, Chandra M, Speiser PW (2008) Growth hormone
improves growth rate and preserves renal function in Dent disease. J
Pediatr Endocrinol Metab 21:279–286
58. Takemura T, Hino S, Ikeda M, Okada M, Igarashi T, Inatomi J,
Yoshioka K (2001) Identification of two novel mutations in the
CLCN5 gene in Japanese patients with familial idiopathic low mo-
lecular weight proteinuria (Japanese Dent’s disease). Am J Kidney
Dis 37:138–143
59. Tasic V, Lozanovski VJ, Korneti P, Ristoska-Bojkovska N, Sabolic-
Avramovska V, Gucev Z, LudwigM (2011) Clinical and laboratory
features of Macedonian children with OCRL mutations. Pediatr
Nephrol 26:557–562
60. Tosetto E, Addis M, Caridi G, Meloni C, Emma F, Vergine G,
Stringini G, Papalia T, Barbano G, Ghiggeri GM, Ruggeri L,
Miglietti N, Da A, Melis MA, Anglani F (2009) Locus heterogene-
ity of Dent’s disease: OCRL1 and TMEM27 genes in patients with
no CLCN5 mutations. Pediatr Nephrol 24:1967–1973
61. Tosetto E, Ghiggeri GM, Emma F, BarbanoG, Carrea A, Vezzoli G,
Torregrossa R, CaraM, Ripanti G, Ammenti A, Peruzzi L,Murer L,
Ratsch IM, Citron L, Gambaro G, D’Angelo A, Anglani F (2006)
Phenotypic and genetic heterogeneity in Dent’s disease–the results
of an Italian collaborative study. Nephrol Dial Transplant 21:2452–
2463
62. Utsch B, Bokenkamp A, Benz MR, Besbas N, Dotsch J, Franke I,
Frund S, Gok F, Hoppe B, Karle S, Kuwertz-Broking E, Laube G,
Neb M, Nuutinen M, Ozaltin F, Rascher W, Ring T, Tasic V, van
Wijk JA, Ludwig M (2006) Novel OCRL1 mutations in patients
with the phenotype of Dent disease. Am J Kidney Dis 48(942):e1–
14
63. Vaisbich MH, Henriques Ldos S, Igarashi T, Sekine T, Seki G,
Koch VH (2012) The long-term use of enalapril and hydrochloro-
thiazide in two novel mutations patients with Dent’s disease type 1.
J Bras Nefrol 34:78–81
64. Yanagida H, Ikeoka M, Kuwajima H,Wada N, Tabata N, Sugimoto
K, Okada M, Takemura T (2004) A boy with Japanese Dent’s
disease exhibiting abnormal calcium metabolism and osseous dis-
order of the spine: defective megalin expression at the brushborder
of renal proximal tubules. Clin Nephrol 62:306–312
65. ZhangH,Wang C,YueH, HuWW,Gu JM, He JW, FuWZ, Liu YJ,
Zhang Z, Zhang ZL (2014) Identification of a novel mutation in the
CLCN5 gene in a Chinese family with Dent-1 disease. Nephrology
(Carlton) 19:80–83
66. Yildiz N, Deniz NC, Altuntas U, Gokce I, Alpay H (2013) Dent’s
disease in a child with nephrolithiasis. Turk J Pediatr 48:347–349
67. Ji LN, Chen CY, Wang JJ, Cao L (2014) A novel CLCN5 mutation
in a Chinese boy with Dent’s disease. World J Pediatr 10:275–277
68. Herget-Rosenthal S, van Wijk JA, Brocker-Preuss M, Bokenkamp
A (2007) Increased urinary cystatin C reflects structural and func-
tional renal tubular impairment independent of glomerular filtration
rate. Clin Biochem 40:946–951
69. Ceol M, Tiralongo E, Baelde HJ, Vianello D, Betto G, Marangelli
A, Bonfante L, Valente M, Della Barbera M, D’Angelo A, Anglani
F, Del Prete D (2012) Involvement of the tubular ClC-type ex-
changer ClC-5 in glomeruli of human proteinuric nephropathies.
PLoS One 7:e45605
70. Erb BC, Velazquez H, Gisser M, Shugrue CA, Reilly RF (1997)
cDNA cloning and localization of OCRL-1 in rabbit kidney. Am J
Physiol 273:F790–795
71. Tojo A, Kinugasa S (2012) Mechanisms of glomerular albumin
filtration and tubular reabsorption. Int J Nephrol 2012:481520
72. Dickson LE, Wagner MC, Sandoval RM, Molitoris BA (2014) The
proximal tubule and albuminuria: really! J Am Soc Nephrol 25:
443–453
73. Ovunc B, Otto EA, Vega-Warner V, Saisawat P, Ashraf S,
Ramaswami G, Fathy HM, Schoeb D, Chernin G, Lyons RH,
Yilmaz E, Hildebrandt F (2011) Exome sequencing reveals cubilin
mutation as a single-gene cause of proteinuria. J Am Soc Nephrol
22:1815–1820
74. Theilig F, Kriz W, Jerichow T, Schrade P, Hahnel B, Willnow T, Le
Hir M, Bachmann S (2007) Abrogation of protein uptake through
megalin-deficient proximal tubules does not safeguard against
tubulointerstitial injury. J Am Soc Nephrol 18:1824–1834
75. Lee PT, Chou KJ, Fang HC (2012) Are tubular cells not only vic-
tims but also perpetrators in renal fibrosis? Kidney Int 82:128–130
76. Grgic I, Campanholle G, Bijol V, Wang C, Sabbisetti VS, Ichimura
T, Humphreys BD, Bonventre JV (2012) Targeted proximal tubule
injury triggers interstitial fibrosis and glomerulosclerosis. Kidney
Int 82:172–183
77. Heerspink HJ, Gansevoort RT (2015) Albuminuria is an appropri-
ate therapeutic target in patients with CKD: the Pro view. Clin J Am
Soc Nephrol 10:1079–1088
78. Cebotaru V, Kaul S, Devuyst O, Cai H, Racusen L, Guggino WB,
Guggino SE (2005) High citrate diet delays progression of renal
insufficiency in the ClC-5 knockout mouse model of Dent’s dis-
ease. Kidney Int 68:642–652
79. Raja KA, Schurman S, D’Mello RG, Blowey D, Goodyer P, Van
Why S, Ploutz-Snyder RJ, Asplin J, Scheinman SJ (2002)
Responsiveness of hypercalciuria to thiazide in Dent’s disease. J
Am Soc Nephrol 13:2938–2944
Pediatr Nephrol
